Logo image of ARGX

ARGENX SE - ADR (ARGX) Stock Fundamental Analysis

NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR

640.52  -19.29 (-2.92%)

After market: 643.74 +3.22 (+0.5%)

Fundamental Rating

4

Taking everything into account, ARGX scores 4 out of 10 in our fundamental rating. ARGX was compared to 572 industry peers in the Biotechnology industry. While ARGX seems to be doing ok healthwise, there are quite some concerns on its profitability. ARGX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ARGX had negative earnings in the past year.
ARGX had a negative operating cash flow in the past year.
ARGX had negative earnings in each of the past 5 years.
In the past 5 years ARGX reported 4 times negative operating cash flow.
ARGX Yearly Net Income VS EBIT VS OCF VS FCFARGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200M -400M -600M -800M

1.2 Ratios

ARGX has a Return On Assets of -5.77%. This is amongst the best in the industry. ARGX outperforms 89.03% of its industry peers.
With an excellent Return On Equity value of -6.50%, ARGX belongs to the best of the industry, outperforming 91.68% of the companies in the same industry.
Industry RankSector Rank
ROA -5.77%
ROE -6.5%
ROIC N/A
ROA(3y)-14.49%
ROA(5y)-16.28%
ROE(3y)-16.18%
ROE(5y)-20.05%
ROIC(3y)N/A
ROIC(5y)N/A
ARGX Yearly ROA, ROE, ROICARGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

With an excellent Gross Margin value of 89.36%, ARGX belongs to the best of the industry, outperforming 92.21% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ARGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARGX Yearly Profit, Operating, Gross MarginsARGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARGX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARGX has more shares outstanding
The debt/assets ratio for ARGX is higher compared to a year ago.
ARGX Yearly Shares OutstandingARGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ARGX Yearly Total Debt VS Total AssetsARGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B

2.2 Solvency

ARGX has an Altman-Z score of 44.88. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 44.88, ARGX belongs to the best of the industry, outperforming 98.05% of the companies in the same industry.
ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.01, ARGX perfoms like the industry average, outperforming 44.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 44.88
ROIC/WACCN/A
WACC7.2%
ARGX Yearly LT Debt VS Equity VS FCFARGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 8.53 indicates that ARGX has no problem at all paying its short term obligations.
The Current ratio of ARGX (8.53) is better than 74.69% of its industry peers.
A Quick Ratio of 7.88 indicates that ARGX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.88, ARGX is doing good in the industry, outperforming 72.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.53
Quick Ratio 7.88
ARGX Yearly Current Assets VS Current LiabilitesARGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.85% over the past year.
Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 62.02%.
Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 120.70% on average per year.
EPS 1Y (TTM)78.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%211.2%
Revenue 1Y (TTM)62.02%
Revenue growth 3Y209.8%
Revenue growth 5Y120.7%
Sales Q2Q%73.28%

3.2 Future

ARGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.67% yearly.
ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.31% yearly.
EPS Next Y84.75%
EPS Next 2Y80.45%
EPS Next 3Y69.93%
EPS Next 5Y51.67%
Revenue Next Year74.5%
Revenue Next 2Y62.44%
Revenue Next 3Y52.25%
Revenue Next 5Y36.31%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARGX Yearly Revenue VS EstimatesARGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
ARGX Yearly EPS VS EstimatesARGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 40 60

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARGX. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 90.20, ARGX can be considered very expensive at the moment.
ARGX's Price/Forward Earnings ratio is rather cheap when compared to the industry. ARGX is cheaper than 91.50% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ARGX to the average of the S&P500 Index (24.11), we can say ARGX is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 90.2
ARGX Price Earnings VS Forward Price EarningsARGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARGX Per share dataARGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 69.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y80.45%
EPS Next 3Y69.93%

More info and screens

0

5. Dividend

5.1 Amount

ARGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARGENX SE - ADR

NASDAQ:ARGX (1/17/2025, 8:00:00 PM)

After market: 643.74 +3.22 (+0.5%)

640.52

-19.29 (-2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)N/A N/A
Inst Owners39.77%
Inst Owner Change-0.05%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap38.30B
Analysts81.67
Price Target616.67 (-3.72%)
Short Float %3.29%
Short Ratio6.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)59.25%
Min EPS beat(2)-26.77%
Max EPS beat(2)145.26%
EPS beat(4)2
Avg EPS beat(4)31.06%
Min EPS beat(4)-26.77%
Max EPS beat(4)145.26%
EPS beat(8)5
Avg EPS beat(8)33.89%
EPS beat(12)9
Avg EPS beat(12)29.37%
EPS beat(16)11
Avg EPS beat(16)35.2%
Revenue beat(2)1
Avg Revenue beat(2)4.46%
Min Revenue beat(2)-0.25%
Max Revenue beat(2)9.17%
Revenue beat(4)3
Avg Revenue beat(4)6.89%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)11.26%
Revenue beat(8)7
Avg Revenue beat(8)19.16%
Revenue beat(12)10
Avg Revenue beat(12)22.15%
Revenue beat(16)12
Avg Revenue beat(16)38.07%
PT rev (1m)-0.32%
PT rev (3m)6.52%
EPS NQ rev (1m)10.54%
EPS NQ rev (3m)131.31%
EPS NY rev (1m)-10.54%
EPS NY rev (3m)12.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)5.55%
Revenue NY rev (3m)5.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 90.2
P/S 19.69
P/FCF N/A
P/OCF N/A
P/B 8.99
P/tB 9.3
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)7.1
Fwd EY1.11%
FCF(TTM)-5.44
FCFYN/A
OCF(TTM)-4.34
OCFYN/A
SpS32.53
BVpS71.28
TBVpS68.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.77%
ROE -6.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.36%
FCFM N/A
ROA(3y)-14.49%
ROA(5y)-16.28%
ROE(3y)-16.18%
ROE(5y)-20.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56%
Cap/Sales 3.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.53
Quick Ratio 7.88
Altman-Z 44.88
F-Score4
WACC7.2%
ROIC/WACCN/A
Cap/Depr(3y)736.22%
Cap/Depr(5y)853.41%
Cap/Sales(3y)17.76%
Cap/Sales(5y)25.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%211.2%
EPS Next Y84.75%
EPS Next 2Y80.45%
EPS Next 3Y69.93%
EPS Next 5Y51.67%
Revenue 1Y (TTM)62.02%
Revenue growth 3Y209.8%
Revenue growth 5Y120.7%
Sales Q2Q%73.28%
Revenue Next Year74.5%
Revenue Next 2Y62.44%
Revenue Next 3Y52.25%
Revenue Next 5Y36.31%
EBIT growth 1Y48.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.23%
EBIT Next 3Y75.76%
EBIT Next 5Y55.78%
FCF growth 1Y62.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.38%
OCF growth 3YN/A
OCF growth 5YN/A